My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Tusamitamab Biosimilar, CEACAM5 Monoclonal Antibody

Tusamitamab Biosimilar, CEACAM5 Monoclonal Antibody

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5

Catalog No. Product Name Size List Price (US$) Quantity
C109P Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody 1 mg 175.00
C109P Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody 5 mg 600.00
C109P Tusamitamab Biosimilar, Human CEACAM5 Monoclonal Antibody 20 mg 1200.00
C109P.NA Tusamitamab Biosimilar, N297A Mutant 0.5 mg 375.00
C109P.NA.05 Tusamitamab Biosimilar, N297A Mutant, Endotoxin 0.05 EU/mg 0.5 mg 575.00
C109P.LA Tusamitamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 0.5 mg 375.00

C109P: Tusamitamab Biosimilar, CEACAM5 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CEACAM5 monoclonal antibody tusamitamab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade tusamitamab biosimilar specifically binds to the CEACAM5 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tusamitamab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade tusamitamab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.


What is tusamitamab biosimilar research grade? Tusamitamab is a humanized IgG1-kappa monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) which is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is an attractive target for therapies based on CAR-T cell or/and ADCs. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) combining a humanized monoclonal antibody and a potent cytotoxic maytansinoid derivative (DM4) inhibiting microtubule assembly. Tusamitamab biosimilar uses the same protein sequences as the therapeutic antibody tusamitamab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy